Acurx Pharmaceuticals (ACXP) CEO awarded 37,100 stock options at $2.36

Rhea-AI Filing Summary

Acurx Pharmaceuticals, Inc. reported that President and CEO David P. Luci received a grant of stock options. On April 20, 2026, he was granted options to purchase 37,100 shares of common stock at an exercise price of $2.36 per share.

The options vest in 36 equal monthly installments starting on the grant date and expire on April 20, 2036. Following this grant, he holds 37,100 stock options directly, each tied to one underlying share of Acurx common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LUCI DAVID P

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	37,100	$0.00	--

Holdings After Transaction: Stock Option — 37,100 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 37,100 options Exercise price: $2.36 per share Vesting schedule: 36 monthly installments +2 more

5 metrics

Options granted 37,100 options Grant to CEO on April 20, 2026

Exercise price $2.36 per share Stock option grant strike price

Vesting schedule 36 monthly installments Vesting begins on April 20, 2026

Expiration date April 20, 2036 Stock options expiry

Options held after grant 37,100 options Total stock options following transaction

Key Terms

Stock Option, Grant Date, vest, exercise price, +1 more

5 terms

Stock Option financial

"the Reporting Person was granted stock options to purchase 37,100 shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Grant Date financial

"On April 20, 2026 (the "Grant Date"), the Reporting Person was granted"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vest financial

"These options vest in 36 equal monthly installments commencing on the Grant Date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price": "2.3600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-04-20T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LUCI DAVID P

(Last) (First) (Middle)

C/O ACURX PHARMACEUTICALS, INC.,

259 LIBERTY AVENUE

(Street)

STATEN ISLAND NEW YORK 10305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acurx Pharmaceuticals, Inc. [ ACXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.36	04/20/2026		A		37,100		(1)	04/20/2036	Common Stock	37,100	$0	37,100	D

Explanation of Responses:

1. On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.

	/s/ Kostantinos Skordalos, Power of Attorney for: David P. Luci	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Acurx Pharmaceuticals (ACXP) report for David P. Luci?

Acurx Pharmaceuticals reported that President and CEO David P. Luci received a grant of stock options. On April 20, 2026, he was awarded options covering 37,100 shares of common stock, structured as a compensation-related grant rather than an open-market share purchase or sale.

How many stock options did the Acurx (ACXP) CEO receive in this Form 4?

The CEO received stock options for 37,100 shares of Acurx common stock. Each option relates to one underlying share, and the entire 37,100 options are shown as held directly after the transaction, reflecting this single grant reported in the Form 4 filing.

What is the exercise price of the Acurx (ACXP) stock options granted to the CEO?

The stock options granted to the CEO have an exercise price of $2.36 per share. This means he can choose to purchase Acurx common stock at $2.36 for each option, subject to the vesting schedule and the April 20, 2036 expiration date.

When do the Acurx Pharmaceuticals (ACXP) CEO’s new stock options vest?

The CEO’s new stock options vest in 36 equal monthly installments starting on April 20, 2026. This monthly vesting structure gradually makes portions of the 37,100 options exercisable over three years, aligning the grant with ongoing service to the company.

When do the Acurx (ACXP) stock options granted to the CEO expire?

The stock options granted to the CEO expire on April 20, 2036. He can exercise vested portions of the 37,100 options at $2.36 per share any time before this expiration date, subject to the company’s equity plan and applicable rules.

Is the Acurx (ACXP) CEO’s Form 4 transaction a market buy or sell?

The Form 4 reflects a grant of stock options, not an open-market buy or sell of shares. The transaction is coded as an acquisition related to compensation, giving the CEO the right to purchase 37,100 shares at $2.36 per share over time.